Applications of gelsemine, koumine and 1-methoxyl gelsemine to preparation of medicine for treating anxiety

A technology for Gyokosin and anxiety disorder, which is applied to the application field of Gyokosin A, Gyokosin, and 1-methoxycryphrine in the preparation of medicines for treating anxiety disorders, can solve uninvolved and other problems, and achieve no Tolerance, less side effects, less addictive effects

Active Publication Date: 2013-03-27
FUJIAN MEDICAL UNIV
View PDF1 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the existing research on the activity of kinesin alkaloid monomers does not involve the research on its anti-anxiety effect. The anxiolytic effects of kinesin A, kelesin, 1-methoxykelesine and their possible uses Unseen literature and patent reports

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of gelsemine, koumine and 1-methoxyl gelsemine to preparation of medicine for treating anxiety
  • Applications of gelsemine, koumine and 1-methoxyl gelsemine to preparation of medicine for treating anxiety
  • Applications of gelsemine, koumine and 1-methoxyl gelsemine to preparation of medicine for treating anxiety

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Inhibitory effect of kelezin A, kelezin, and 1-methoxygelsinine on the anxiety behavior of mice in the elevated plus maze by subcutaneous injection in the back of the neck.

[0041] 1.1 Drugs and reagents:

[0042] Kiskinin A, Kiskinin, 1-methoxykiskinine are obtained by the applicant of the present invention from the natural plant Kissine extraction, separation and purification, with a purity of >98.5% (precisely weighed Kiskinin A, Kiskinin, 1- Gelsine, dissolved in 1mol / l HCl, diluted with normal saline, adjusted pH with 1mol / l NaOH (4

[0043] 1.2 Animals:

[0044] Kunming mice, male, 18-22g, provided by the Experimental Animal Center of Fujian Medical University. They were raised at room temperature at 25°C under a light-dark cycle of 12 / 12h, free to eat and drink, and...

Embodiment 2

[0058] Inhibitory effects of kelezin A, kelezin, and 1-methoxygerelazine administered subcutaneously on the back of the neck on the anxiety behavior of mice in the light and dark box.

[0059] 2.1 Drugs and reagents:

[0060] Kiskinin A, Kiskinin, 1-methoxykiskinine are obtained by the applicant of the present invention from the natural plant Kissine extraction, separation and purification, with a purity of >98.5% (precisely weighed Kiskinin A, Kiskinin, 1- Gelsine, dissolved in 1mol / l HCl, diluted with normal saline, adjusted pH with 1mol / l NaOH (4

[0061] 2.2 Animals:

[0062] Kunming mice, male, 18-22g, provided by the Experimental Animal Center of Fujian Medical University. They were raised at room temperature at 25°C under a light-dark cycle of 12 / 12h, free to eat and drink,...

Embodiment 3

[0076] Experiment on the median lethal dose of total geskinine alkaloids, geskinin A, geskinin and 1-methoxygeskinine subcutaneously injected into the back of the neck of mice

[0077] 2.1 Drugs and reagents:

[0078] The total alkaloids of kinesin, kinesin A, kinesin, and 1-methoxy gesine were obtained by the applicant of the present invention from the extraction, separation and purification of the natural plant kinesin, with a purity of >98.5% (precisely weighed kinesin A, Kiskinin and 1-methoxygynecine, dissolved in 1mol / l HCl, diluted with normal saline, adjusted to pH (4

[0079] 2.2 Animals:

[0080] Kunming mice, male, 18-22g, provided by the Experimental Animal Center of Fujian Medical University. They were raised at room temperature at 25°C under a light-dark cycle of 12 / 12h, free to eat and drink, and used for formal experiments after 3 days of adaptation to t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses the application of kelesin A, kelesin, and 1-methoxygerisine in the preparation of drugs for treating anxiety, especially the kelesin alkaloid monomer kelesin A as the only active ingredient or its pharmaceutical preparations. The application of above acceptable salt in the preparation of medicine for treating anxiety disorder; the application of kinesin alkaloid monomer kelezin or its pharmaceutically acceptable salt as the only active ingredient in the preparation of medicine for treating anxiety disorder; as the only active ingredient The application of the geskin alkaloid monomer 1-methoxygesine or a pharmaceutically acceptable salt thereof in the preparation of drugs for treating anxiety; Alkaloids can play a significant role in mouse anxiety at a dose much lower than poisoning, significantly expand the safe treatment window, have no tolerance, addiction and small side effects, and are more suitable for preparation and treatment than total alkaloids Anxiety medication.

Description

Technical field [0001] The invention involves the application of hook-kiss alkaline monomers, especially the application of GelSemine, hook kissin, and 1-metharma-based hook-kiss alkali in preparing for the treatment of anxiety. Background technique [0002] Anxiety, also known as anxiety neurosis, is a common disease. According to clinical manifestations, it can be divided into two types: panic disorder and extensive anxiety.According to relevant US data reports, about 490 million people in the world suffer from anxiety, and the lifelong prevalence in the crowd is 5%; the prevalence of domestic reports has reached 2%to 3%.If anxiety is not treated for a long time, 40%to 50%of patients may evolve into depression.Drug resistance is one of the main methods of clinical treatment of patient anxiety. A cutting -edge strategic consulting (FLSC) company entitled"Anti -anxiety: Strategic market analysis of the United States and the worldThe current treatment and new treatment drugs of th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/439A61P25/22
Inventor 俞昌喜刘铭许盈苏燕评杨渐
Owner FUJIAN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap